167 related articles for article (PubMed ID: 38231347)
1. Management of Atopy with Dupilumab and Omalizumab in CADINS Disease.
Diaz-Cabrera NM; Bauman BM; Iro MA; Dabbah-Krancher G; Molho-Pessach V; Zlotogorski A; Shamriz O; Dinur-Schejter Y; Sharon TD; Stepensky P; Tal Y; Eisenstein EM; Pietzsch L; Schuetz C; Abreu D; Coughlin CC; Cooper MA; Milner JD; Williams A; Armoni-Weiss G; Snow AL; Leiding JW
J Clin Immunol; 2024 Jan; 44(2):48. PubMed ID: 38231347
[TBL] [Abstract][Full Text] [Related]
2. Hyper-IgE and Carcinoma in CADINS Disease.
Pietzsch L; Körholz J; Boschann F; Sergon M; Dorjbal B; Yee D; Gilly V; Kämmerer E; Paul D; Kastl C; Laass MW; Berner R; Jacobsen EM; Roesler J; Aust D; Lee-Kirsch MA; Snow AL; Schuetz C
Front Immunol; 2022; 13():878989. PubMed ID: 35651609
[TBL] [Abstract][Full Text] [Related]
3.
Hutcherson SM; Bedsaul JR; Pomerantz JL
J Immunol; 2021 Aug; 207(4):1150-1164. PubMed ID: 34341167
[TBL] [Abstract][Full Text] [Related]
4. Expanding spectrum, intrafamilial diversity, and therapeutic challenges from 15 patients with heterozygous CARD11-associated diseases: A single center experience.
Urdinez L; Erra L; Palma AM; Mercogliano MF; Fernandez JB; Prieto E; Goris V; Bernasconi A; Sanz M; Villa M; Bouso C; Caputi L; Quesada B; Solis D; Aguirre Bruzzo A; Katsicas MM; Galluzzo L; Weyersberg C; Bocian M; Bujan MM; Oleastro M; Almejun MB; Danielian S
Front Immunol; 2022; 13():1020927. PubMed ID: 36405754
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of simultaneously occurring urticaria and atopic dermatitis with dupilumab].
Föhr J; Herbst M; Jahn S
Hautarzt; 2021 Mar; 72(3):249-251. PubMed ID: 32856123
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab for treatment of refractory severe atopic dermatitis. A pediatric perspective.
Iannelli M; Caminiti L; Vaccaro M; Marafioti I; Spinuzza A; Panasiti I; Barbalace A; Crisafulli G; Pajno GB
Dermatol Ther; 2020 Jul; 33(4):e13519. PubMed ID: 32378300
[TBL] [Abstract][Full Text] [Related]
7. Concurrent use of omalizumab and dupilumab in a 47-year-old woman with chronic spontaneous urticaria and atopic dermatitis.
Holm JG; Sørensen JA; Thomsen SF
Int J Dermatol; 2022 May; 61(5):e173-e174. PubMed ID: 34813086
[No Abstract] [Full Text] [Related]
8. Immunobiologic treatments for severe asthma, atopic dermatitis, and chronic urticaria.
Chiarella SE
Allergy Asthma Proc; 2019 Nov; 40(6):485-489. PubMed ID: 31690400
[TBL] [Abstract][Full Text] [Related]
9. Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial.
Chan S; Cornelius V; Cro S; Harper JI; Lack G
JAMA Pediatr; 2020 Jan; 174(1):29-37. PubMed ID: 31764962
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab an effective and safe alternative therapy in severe refractory atopic dermatitis: A case report.
Sirufo MM; De Martinis M; Ginaldi L
Medicine (Baltimore); 2018 Jun; 97(24):e10897. PubMed ID: 29901580
[TBL] [Abstract][Full Text] [Related]
11. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
Bosma AL; de Wijs LEM; Hof MH; van Nieuwenhuizen BR; Gerbens LAA; Middelkamp-Hup MA; Hijnen D; Spuls PI
J Am Acad Dermatol; 2020 Nov; 83(5):1375-1384. PubMed ID: 32485210
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review.
Hendricks AJ; Yosipovitch G; Shi VY
J Dermatolog Treat; 2021 Feb; 32(1):19-28. PubMed ID: 31693426
[No Abstract] [Full Text] [Related]
14. Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease.
Dorjbal B; Stinson JR; Ma CA; Weinreich MA; Miraghazadeh B; Hartberger JM; Frey-Jakobs S; Weidinger S; Moebus L; Franke A; Schäffer AA; Bulashevska A; Fuchs S; Ehl S; Limaye S; Arkwright PD; Briggs TA; Langley C; Bethune C; Whyte AF; Alachkar H; Nejentsev S; DiMaggio T; Nelson CG; Stone KD; Nason M; Brittain EH; Oler AJ; Veltri DP; Leahy TR; Conlon N; Poli MC; Borzutzky A; Cohen JI; Davis J; Lambert MP; Romberg N; Sullivan KE; Paris K; Freeman AF; Lucas L; Chandrakasan S; Savic S; Hambleton S; Patel SY; Jordan MB; Theos A; Lebensburger J; Atkinson TP; Torgerson TR; Chinn IK; Milner JD; Grimbacher B; Cook MC; Snow AL
J Allergy Clin Immunol; 2019 Apr; 143(4):1482-1495. PubMed ID: 30170123
[TBL] [Abstract][Full Text] [Related]
15. Dual biologic therapy with Omalizumab and Dupilumab for refractory atopic disease.
Arasu A; Sharma N; Yazdabadi A; Sladden M
Australas J Dermatol; 2022 Feb; 63(1):110-111. PubMed ID: 34755893
[No Abstract] [Full Text] [Related]
16. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
17. A Unique Heterozygous
Desjardins M; Arjunaraja S; Stinson JR; Dorjbal B; Sundaresan J; Niemela J; Raffeld M; Matthews HF; Wang A; Angelus P; Su HC; Mazer BD; Snow AL
Front Immunol; 2018; 9():2944. PubMed ID: 30619304
[TBL] [Abstract][Full Text] [Related]
18. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children.
Parker JJ; Sugarman JL; Silverberg NB; Gonzalez ME; Ramien ML; Teng JMC; Paller AS
Pediatr Dermatol; 2021 Nov; 38(6):1500-1505. PubMed ID: 34647354
[TBL] [Abstract][Full Text] [Related]
19. Prurigo-like atopic dermatitis in a child with CARD11-associated severe combined immunodeficiency successfully treated with dupilumab.
Gualdi G; Lougaris V; Amerio P; Petruzzellis A; Parodi A; Burlando M
Pediatr Dermatol; 2024; 41(1):158-159. PubMed ID: 37888582
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.
Silverberg JI; Simpson EL; Boguniewicz M; De Bruin-Weller MS; Foley P; Kataoka Y; Bégo-Le-Bagousse G; Chen Z; Shumel B; Chao J; Rossi AB
Acta Derm Venereol; 2021 Nov; 101(11):adv00585. PubMed ID: 34618162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
